Search

Your search keyword '"Cirillo, Daniela M."' showing total 468 results
Start Over Author "Cirillo, Daniela M."
468 results on '"Cirillo, Daniela M."'

4. Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment

Author

Georghiou, Sophia B, Rodwell, Timothy C, Korobitsyn, Alexei, Abbadi, Said H, Ajbani, Kanchan, Alffenaar, Jan-Willem, Alland, David, Alvarez, Nataly, Andres, Sönke, Ardizzoni, Elisa, Aubry, Alexandra, Baldan, Rossella, Ballif, Marie, Barilar, Ivan, Böttger, Erik C, Chakravorty, Soumitesh, Claxton, Pauline M, Cirillo, Daniela M, Comas, Iñaki, Coulter, Chris, Denkinger, Claudia M, Derendinger, Brigitta, Desmond, Edward P, de Steenwinkel, Jurriaan EM, Dheda, Keertan, Diacon, Andreas H, Dolinger, David L, Dooley, Kelly E, Egger, Matthias, Ehsani, Soudeh, Farhat, Maha R, Fattorini, Lanfranco, Finci, Iris, Le Ray, Laure Fournier, Furió, Victoria, Groenheit, Ramona, Gumbo, Tawanda, Heysell, Scott K, Hillemann, Doris, Hoffmann, Harald, Hsueh, Po-Ren, Hu, Yi, Huang, Hairong, Hussain, Alamdar, Ismail, Farzana, Izumi, Kiyohiko, Jagielski, Tomasz, Johnson, John L, Kambli, Priti, Kaniga, Koné, Karunaratne, GHR Eranga, Sharma, Meenu Kaushal, Keller, Peter M, Kelly, Ellis C, Kholina, Margarita, Kohli, Mikashmi, Kranzer, Katharina, Laurenson, Ian F, Limberis, Jason, Lin, S-Y Grace, Liu, Yongge, López-Gavín, Alexandre, Lyander, Anna, Machado, Diana, Martinez, Elena, Masood, Faisal, Mitarai, Satoshi, Mvelase, Nomonde R, Niemann, Stefan, Nikolayevskyy, Vladyslav, Maurer, Florian P, Merker, Matthias, Miotto, Paolo, Omar, Shaheed V, Otto-Knapp, Ralf, Palaci, Moisés, Gutiérrez, Juan José Palacios, Peacock, Sharon J, Peloquin, Charles A, Perera, Jennifer, Pierre-Audigier, Catherine, Pholwat, Suporn, Posey, James E, Prammananan, Therdsak, Rigouts, Leen, Robledo, Jaime, Rockwood, Neesha, Rodrigues, Camilla, Salfinger, Max, Schechter, Marcos C, Seifert, Marva, Sengstake, Sarah, Shinnick, Thomas, Shubladze, Natalia, Sintchenko, Vitali, Sirgel, Frederick, Somasundaram, Sulochana, Sterling, Timothy R, Spitaleri, Andrea, and Streicher, Elizabeth

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Clinical Sciences, Orphan Drug, Emerging Infectious Diseases, Tuberculosis, Biodefense, Antimicrobial Resistance, Infectious Diseases, Rare Diseases, 5.1 Pharmaceuticals, 6.1 Pharmaceuticals, Infection, Good Health and Well Being, Antitubercular Agents, Drug Resistance, Bacterial, Drug Resistance, Multiple, Bacterial, Humans, Microbial Sensitivity Tests, Mycobacterium tuberculosis, Tuberculosis, Multidrug-Resistant, Antimycobacterial Susceptibility Testing Group, Medical and Health Sciences, Respiratory System, Cardiovascular medicine and haematology
Abstract

Inappropriately high breakpoints have resulted in systematic false-susceptible AST results to anti-TB drugs. MIC, PK/PD and clinical outcome data should be combined when setting breakpoints to minimise the emergence and spread of antimicrobial resistance. https://bit.ly/3i43wb6

Published
2022

5. Author Correction: Integrating standardized whole genome sequence analysis with a global Mycobacterium tuberculosis antibiotic resistance knowledgebase

Author

Ezewudo, Matthew, Borens, Amanda, Chiner-Oms, Álvaro, Miotto, Paolo, Chindelevitch, Leonid, Starks, Angela M, Hanna, Debra, Liwski, Richard, Zignol, Matteo, Gilpin, Christopher, Niemann, Stefan, Kohl, Thomas Andreas, Warren, Robin M, Crook, Derrick, Gagneux, Sebastien, Hoffner, Sven, Rodrigues, Camilla, Comas, Iñaki, Engelthaler, David M, Alland, David, Rigouts, Leen, Lange, Christoph, Dheda, Keertan, Hasan, Rumina, McNerney, Ruth, Cirillo, Daniela M, Schito, Marco, Rodwell, Timothy C, and Posey, James

Subjects
Microbiology, Biological Sciences, Infection, Good Health and Well Being
Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Published
2020

6. Application of Targeted Next-Generation Sequencing Assay on a Portable Sequencing Platform for Culture-Free Detection of Drug-Resistant Tuberculosis from Clinical Samples

Author

Cabibbe, Andrea M, Spitaleri, Andrea, Battaglia, Simone, Colman, Rebecca E, Suresh, Anita, Uplekar, Swapna, Rodwell, Timothy C, and Cirillo, Daniela M

Subjects
Human Genome, Rare Diseases, Infectious Diseases, Genetics, Tuberculosis, Antimicrobial Resistance, HIV/AIDS, Biotechnology, 4.1 Discovery and preclinical testing of markers and technologies, Detection, screening and diagnosis, Infection, Good Health and Well Being, High-Throughput Nucleotide Sequencing, Humans, Microbial Sensitivity Tests, Mycobacterium tuberculosis, Sequence Analysis, DNA, Tuberculosis, Multidrug-Resistant, direct test, drug-resistant tuberculosis, next-generation sequencing, portable sequencer, rapid drug susceptibility testing, Biological Sciences, Agricultural and Veterinary Sciences, Medical and Health Sciences, Microbiology
Abstract

Targeted next-generation sequencing (tNGS) has emerged as a comprehensive alternative to existing methods for drug susceptibility testing (DST) of Mycobacterium tuberculosis from patient sputum samples for clinical diagnosis of drug-resistant tuberculosis (DR-TB). However, the complexity of sequencing platforms has limited their uptake in low-resource settings. The goal of this study was to evaluate the use of the tNGS-based DST solution Genoscreen Deeplex Myc-TB, for use on the compact, low-cost Oxford Nanopore Technologies MinION sequencer. One hundred four DNA samples extracted from smear-positive sputum sediments, previously sequenced using the Deeplex assay on an Illumina MiniSeq, were resequenced on MinION after applying a custom library preparation. MinION read quality, mapping statistics, and variant calling were computed using an in-house pipeline and compared to the reference MiniSeq data. The average percentage of MinION reads mapped to an H37RV reference genome was 90.8%, versus 99.5% on MiniSeq. The mean depths of coverage were 4,151× and 4,177× on MinION and MiniSeq, respectively, with heterogeneous distribution across targeted genes. Composite reference coverage breadth was >99% for both platforms. We observed full concordance between technologies in reporting the clinically relevant drug-resistant markers, including full gene deletions. In conclusion, we demonstrated that the workflow and sequencing data obtained from Deeplex on MinION are comparable to those for the MiniSeq, despite the higher raw error rates on MinION, with the added advantage of MinION's portability, versatility, and low capital costs. Targeted NGS on MinION is a promising DST solution for rapidly providing clinically relevant data to manage complex DR-TB cases.

Published
2020

8. Building the framework for standardized clinical laboratory reporting of next generation sequencing data for resistance-associated mutations in Mycobacterium tuberculosis complex

Author

Tornheim, Jeffrey A, Starks, Angela M, Rodwell, Timothy C, Gardy, Jennifer L, Walker, Timothy M, Cirillo, Daniela M, Jayashankar, Lakshmi, Miotto, Paolo, Zignol, Matteo, and Schito, Marco

Subjects
Rare Diseases, Infectious Diseases, Tuberculosis, Emerging Infectious Diseases, Antimicrobial Resistance, Genetics, Infection, Good Health and Well Being, Antitubercular Agents, Drug Resistance, Multiple, Bacterial, Genotype, High-Throughput Nucleotide Sequencing, Humans, Microbial Sensitivity Tests, Mutation, Mycobacterium tuberculosis, Sequence Analysis, DNA, Tuberculosis, Multidrug-Resistant, tuberculosis, next-generation sequencing, reporting, standardization, interpretation, Biological Sciences, Medical and Health Sciences, Microbiology
Abstract

Tuberculosis is the primary infectious disease killer worldwide, with a growing threat from multidrug-resistant cases. Unfortunately, classic growth-based phenotypic drug susceptibility testing (DST) remains difficult, costly, and time consuming, while current rapid molecular testing options are limited by the diversity of antimicrobial-resistant genotypes that can be detected at once. Next-generation sequencing (NGS) offers the opportunity for rapid, comprehensive DST without the time or cost burden of phenotypic tests and can provide useful information for global surveillance. As access to NGS expands, it will be important to ensure that results are communicated clearly, consistent, comparable between laboratories, and associated with clear guidance on clinical interpretation of results. In this viewpoint article, we summarize 2 expert workshops regarding a standardized report format, focusing on relevant variables, terminology, and required minimal elements for clinical and laboratory reports with a proposed standardized template for clinical reporting NGS results for Mycobacterium tuberculosis.

Published
2019

12. Integrating standardized whole genome sequence analysis with a global Mycobacterium tuberculosis antibiotic resistance knowledgebase

Author

Ezewudo, Matthew, Borens, Amanda, Chiner-Oms, Álvaro, Miotto, Paolo, Chindelevitch, Leonid, Starks, Angela M, Hanna, Debra, Liwski, Richard, Zignol, Matteo, Gilpin, Christopher, Niemann, Stefan, Kohl, Thomas Andreas, Warren, Robin M, Crook, Derrick, Gagneux, Sebastien, Hoffner, Sven, Rodrigues, Camilla, Comas, Iñaki, Engelthaler, David M, Alland, David, Rigouts, Leen, Lange, Christoph, Dheda, Keertan, Hasan, Rumina, McNerney, Ruth, Cirillo, Daniela M, Schito, Marco, Rodwell, Timothy C, and Posey, James

Subjects
Biological Sciences, Bioinformatics and Computational Biology, Biomedical and Clinical Sciences, Genetics, Microbiology, Clinical Sciences, Human Genome, Tuberculosis, Antimicrobial Resistance, Rare Diseases, Biotechnology, Infectious Diseases, Aetiology, 2.1 Biological and endogenous factors, Infection, Good Health and Well Being, Antitubercular Agents, Bacterial Proteins, Drug Resistance, Multiple, Bacterial, Genome, Bacterial, Genotype, Humans, Knowledge Bases, Mutation, Mycobacterium tuberculosis, Polymorphism, Single Nucleotide, Sequence Analysis, DNA, Tuberculosis, Multidrug-Resistant, Whole Genome Sequencing
Abstract

Drug-resistant tuberculosis poses a persistent public health threat. The ReSeqTB platform is a collaborative, curated knowledgebase, designed to standardize and aggregate global Mycobacterium tuberculosis complex (MTBC) variant data from whole genome sequencing (WGS) with phenotypic drug susceptibility testing (DST) and clinical data. We developed a unified analysis variant pipeline (UVP) ( https://github.com/CPTR-ReSeqTB/UVP ) to identify variants and assign lineage from MTBC sequence data. Stringent thresholds and quality control measures were incorporated in this open source tool. The pipeline was validated using a well-characterized dataset of 90 diverse MTBC isolates with conventional DST and DNA Sanger sequencing data. The UVP exhibited 98.9% agreement with the variants identified using Sanger sequencing and was 100% concordant with conventional methods of assigning lineage. We analyzed 4636 publicly available MTBC isolates in the ReSeqTB platform representing all seven major MTBC lineages. The variants detected have an above 94% accuracy of predicting drug based on the accompanying DST results in the platform. The aggregation of variants over time in the platform will establish confidence-graded mutations statistically associated with phenotypic drug resistance. These tools serve as critical reference standards for future molecular diagnostic assay developers, researchers, public health agencies and clinicians working towards the control of drug-resistant tuberculosis.

Published
2018

13. A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis

Author

Miotto, Paolo, Tessema, Belay, Tagliani, Elisa, Chindelevitch, Leonid, Starks, Angela M, Emerson, Claudia, Hanna, Debra, Kim, Peter S, Liwski, Richard, Zignol, Matteo, Gilpin, Christopher, Niemann, Stefan, Denkinger, Claudia M, Fleming, Joy, Warren, Robin M, Crook, Derrick, Posey, James, Gagneux, Sebastien, Hoffner, Sven, Rodrigues, Camilla, Comas, Iñaki, Engelthaler, David M, Murray, Megan, Alland, David, Rigouts, Leen, Lange, Christoph, Dheda, Keertan, Hasan, Rumina, Ranganathan, Uma Devi K, McNerney, Ruth, Ezewudo, Matthew, Cirillo, Daniela M, Schito, Marco, Köser, Claudio U, and Rodwell, Timothy C

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Infectious Diseases, Tuberculosis, HIV/AIDS, Antimicrobial Resistance, Genetics, Rare Diseases, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Infection, Good Health and Well Being, Antitubercular Agents, Bacterial Proteins, DNA, Bacterial, Data Interpretation, Statistical, Drug Resistance, Multiple, Bacterial, Genotype, Humans, Microbial Sensitivity Tests, Mutation, Mycobacterium tuberculosis, Phenotype, Sequence Analysis, DNA, Systematic Reviews as Topic, Tuberculosis, Multidrug-Resistant, Medical and Health Sciences, Respiratory System, Cardiovascular medicine and haematology
Abstract

A clear understanding of the genetic basis of antibiotic resistance in Mycobacterium tuberculosis is required to accelerate the development of rapid drug susceptibility testing methods based on genetic sequence.Raw genotype-phenotype correlation data were extracted as part of a comprehensive systematic review to develop a standardised analytical approach for interpreting resistance associated mutations for rifampicin, isoniazid, ofloxacin/levofloxacin, moxifloxacin, amikacin, kanamycin, capreomycin, streptomycin, ethionamide/prothionamide and pyrazinamide. Mutation frequencies in resistant and susceptible isolates were calculated, together with novel statistical measures to classify mutations as high, moderate, minimal or indeterminate confidence for predicting resistance.We identified 286 confidence-graded mutations associated with resistance. Compared to phenotypic methods, sensitivity (95% CI) for rifampicin was 90.3% (89.6-90.9%), while for isoniazid it was 78.2% (77.4-79.0%) and their specificities were 96.3% (95.7-96.8%) and 94.4% (93.1-95.5%), respectively. For second-line drugs, sensitivity varied from 67.4% (64.1-70.6%) for capreomycin to 88.2% (85.1-90.9%) for moxifloxacin, with specificity ranging from 90.0% (87.1-92.5%) for moxifloxacin to 99.5% (99.0-99.8%) for amikacin.This study provides a standardised and comprehensive approach for the interpretation of mutations as predictors of M. tuberculosis drug-resistant phenotypes. These data have implications for the clinical interpretation of molecular diagnostics and next-generation sequencing as well as efficient individualised therapy for patients with drug-resistant tuberculosis.

Published
2017

14. Single-Cell RNA Sequencing Shows that Circulating Monocytes Enriched in IFN Signaling Are Associated with Nontuberculous Mycobacteria Pulmonary Disease in Cystic Fibrosis.

Author

Lorè, Nicola I., Gramegna, Andrea, de Pretis, Stefano, Di Marco, Federico, Giannese, Francesca, Saliu, Fabio, Oneto, Caterina, Contarini, Martina, Cariani, Lisa, Blasi, Francesco, and Cirillo, Daniela M.

Subjects
MONONUCLEAR leukocytes, GENE expression, DENSITY gradient centrifugation, KILLER cells, GENE expression profiling, EXOCRINE pancreatic insufficiency
Abstract

This letter discusses a study that used single-cell RNA sequencing to analyze the gene expression profiles of peripheral blood mononuclear cells (PBMCs) in people with cystic fibrosis (pwCFs) who have different stages of Mycobacterium abscessus lung disease. The study identified 10 distinct cell populations within the PBMCs and found that there was no significant cellular variation among pwCFs with different risks of M. abscessus lung disease. However, the CD14+ monocyte cluster in the MABSC-PD group displayed the highest number of upregulated genes compared to other cellular clusters. The study suggests that single-cell transcriptomic profiling of PBMCs could be used to identify diagnostic signatures or therapeutic targets for pwCFs with NTM infection. [Extracted from the article]

Published
2024
Full Text
View/download PDF

15. Characteristics and Clinical Implications of Carbapenemase-Producing Klebsiella pneumonia Colonization and Infection, Italy

Author

Rossi, Marianna, Chatenoud, Liliane, Gona, Floriana, Sala, Isabella, Nattino, Giovanni, D'Antonio, Alessia, Castelli, Daniele, Itri, Teresa, Morelli, Paola, Bigoni, Sara, Aldieri, Chiara, Martegani, Roberto, Grossi, Paolo A., Del Curto, Cecilia, Piconi, Stefania, Rimoldi, Sara G., Brambilla, Paola, Bonfanti, Paolo, Van Hauwermeiren, Evelyn, Puoti, Massimo, Gattuso, Gianni, Cerri, Chiara, Raviglione, Mario C., Cirillo, Daniela M., Bandera, Alessandra, and Gori, Andrea

Subjects
Statistics, Care and treatment, Patient outcomes, Hospital patients -- Statistics, Klebsiella infections -- Statistics -- Patient outcomes -- Care and treatment
Abstract

The global emergence and spread of carbapenem-resistant Enterobacteriaceae (CRE) pose a major health threat, causing severe illness and high healthcare costs (1). Infections caused by CRE also are associated with [...]

Published
2021
Full Text
View/download PDF

17. A composite reference standard is needed for bedaquiline antimicrobial susceptibility testing for Mycobacterium tuberculosis complex

Author

Koeser, Claudio U., Miotto, Paolo, Ismail, Nabila, Anthony, Richard M., Utpatel, Christian, Merker, Matthias, Niemann, Stefan, Tahseen, Sabira, Rigouts, Leen, Rodrigues, Camilla, Omar, Shaheed V., Farhat, Maha R., Antonenka, Uladzimir, Hoffmann, Harald, Cirillo, Daniela M., Schön, Thomas, Koeser, Claudio U., Miotto, Paolo, Ismail, Nabila, Anthony, Richard M., Utpatel, Christian, Merker, Matthias, Niemann, Stefan, Tahseen, Sabira, Rigouts, Leen, Rodrigues, Camilla, Omar, Shaheed V., Farhat, Maha R., Antonenka, Uladzimir, Hoffmann, Harald, Cirillo, Daniela M., and Schön, Thomas

Abstract

Funding Agencies|German Ministry of Health [ZMVI1-2519GHP708]; Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's ' s Excellence Strategy [EXC 2167]; Leibniz Science Campus Evolutionary Medicine of the Lung (EvoLUNG); Belgian Science Policy Office; Flemish government [G0B0222N]; US National Institutes of Health (NIH) [NIAID R01-AI176498, R01-AI155765]; Heart and Lung Foundation (Oscar II Jubilee Foundation) [20220148]; Swedish Research Council [2022-00865, 2022-05263]; Swedish Research Council [2022-05263, 2022-00865] Funding Source: Swedish Research Council

Published
2024
Full Text
View/download PDF

18. Loss-of-function mutations in ndh do not confer delamanid, ethionamide, isoniazid, or pretomanid resistance in Mycobacterium tuberculosis

Author

Pandey, Sushil, Vilcheze, Catherine, Werngren, Jim, Bainomugisa, Arnold, Mansjo, Mikael, Groenheit, Ramona, Miotto, Paolo, Cirillo, Daniela M., Coulter, Christopher, Baulard, Alain R., Schön, Thomas, Jacobs Jr, William R., Djaout, Kamel, Koser, Claudio U., Pandey, Sushil, Vilcheze, Catherine, Werngren, Jim, Bainomugisa, Arnold, Mansjo, Mikael, Groenheit, Ramona, Miotto, Paolo, Cirillo, Daniela M., Coulter, Christopher, Baulard, Alain R., Schön, Thomas, Jacobs Jr, William R., Djaout, Kamel, and Koser, Claudio U.

Abstract

Results from clinical strains and knockouts of the H37Rv and CDC1551 laboratory strains demonstrated that ndh (Rv1854c) is not a resistance-conferring gene for isoniazid, ethionamide, delamanid, or pretomanid in Mycobacterium tuberculosis. This difference in the susceptibility to NAD-adduct-forming drugs compared with other mycobacteria may be driven by differences in the absolute intrabacterial NADH concentration., Funding Agencies|National Institute of Health Grant [ANR-20-PAMR-0005]; PNG National Tuberculosis Programme [AI26170]; National Institute of Health

Published
2024
Full Text
View/download PDF

20. Inflammatory Markers Predict Blood Neurofilament Light Chain Levels in Acute COVID-19 Patients.

Author

De Lorenzo, Rebecca, Loré, Nicola I., Finardi, Annamaria, Mandelli, Alessandra, Calesella, Federico, Palladini, Mariagrazia, Cirillo, Daniela M., Tresoldi, Cristina, Ciceri, Fabio, Rovere-Querini, Patrizia, Manfredi, Angelo A., Mazza, Mario G., Benedetti, Francesco, and Furlan, Roberto

Subjects
COVID-19 pandemic, COVID-19, CYTOPLASMIC filaments, NERVOUS system, ACUTE diseases
Abstract

Acute coronavirus disease 2019 (COVID-19) is paralleled by a rise in the peripheral levels of neurofilament light chain (NfL), suggesting early nervous system damage. In a cohort of 103 COVID-19 patients, we studied the relationship between the NfL and peripheral inflammatory markers. We found that the NfL levels are significantly predicted by a panel of circulating cytokines/chemokines, including CRP, IL-4, IL-8, IL-9, Eotaxin, and MIP-1ß, which are highly up-regulated during COVID-19 and are associated with clinical outcomes. Our findings show that peripheral cytokines influence the plasma levels of the NfL, suggesting a potential role of the NfL as a marker of neuronal damage associated with COVID-19 inflammation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Genetic characterization of Klebsiella pneumoniae carbapenemase -producing Klebsiella pneumoniae isolates with different susceptibility to ceftazidime/avibactam in patients with blood-stream infections

Author

Badalucco Ciotta, Flavia, primary, Saluzzo, Francesca, additional, Pescò, Alessandra, additional, Di Marco, Federico, additional, Carletti, Silvia, additional, Ripa, Marco, additional, Mancini, Nicasio, additional, Cirillo, Daniela M., additional, Castagna, Antonella, additional, and Oltolini, Chiara, additional

Published
2023
Full Text
View/download PDF

23. A cluster of multidrug-resistant Mycobacterium tuberculosis among patients arriving in Europe from the Horn of Africa: a molecular epidemiological study

Author

Avsar, Korkut, Bauer, Christoph, Bernasconi, Enos, Borroni, Emanuele, Brusin, Sergio, Coscollá Dévis, Mireia, Crook, Derrick W., Dedicoat, Martin, Fitzgibbon, Margaret, Gagneux, Sébastien, Geiger, Francisca, Guthmann, Jean-Paul, Hendrickx, David, Hoffmann-Thiel, Sabine, van Ingen, Jakko, Jackson, Sarah, Jaton, Katia, Lange, Christoph, Mazza Stalder, Jessica, O'Donnell, Joan, Opota, Onya, Peto, Tim E.A., Preiswerk, Benjamin, Roycroft, Emma, Sato, Mariko, Schacher, Regina, Schulthess, Bettina, Smith, E. Grace, Soini, Hanna, Sougakoff, Wladimir, Tagliani, Elisa, Utpatel, Christian, Veziris, Nicolas, Wagner-Wiening, Christiane, Witschi, Mark, Walker, Timothy M, Merker, Matthias, Knoblauch, Astrid M, Helbling, Peter, Schoch, Otto D, van der Werf, Marieke J, Kranzer, Katharina, Fiebig, Lena, Kröger, Stefan, Haas, Walter, Hoffmann, Harald, Indra, Alexander, Egli, Adrian, Cirillo, Daniela M, Robert, Jérôme, Rogers, Thomas R, Groenheit, Ramona, Mengshoel, Anne T, Mathys, Vanessa, Haanperä, Marjo, Soolingen, Dick van, Niemann, Stefan, Böttger, Erik C, and Keller, Peter M

Published
2018
Full Text
View/download PDF

24. Drug-Resistant Tuberculosis, Lebanon, 2016-2017

Author

El Achkar, Salam, Demanche, Christine, Osman, Marwan, Rafei, Rayane, Ismail, Mohamad Bachar, Yaacoub, Hiam, Pincon, Claire, Duthoy, Stephanie, de Matos, Frederique, Gaudin, Cyril, Trovato, Alberto, Cirillo, Daniela M., Hamze, Monzer, and Supply, Philip

Subjects
Drug testing, International economic relations, Drug therapy, Bedaquiline, Tuberculosis -- Drug therapy, Rifampin, Refugees -- Drug testing, Microbial drug resistance -- Drug therapy, Migrant labor -- Drug testing, Isoniazid, Malnutrition, Antibacterial agents, Health, Antitubercular agents, Workers, Drug resistance
Abstract

Populations in crisis-affected areas are particularly vulnerable to tuberculosis (TB) linked to malnutrition, overcrowding, and discontinuity in health services (1,2). Difficulties accessing diagnosis and starting or completing appropriate treatment can [...]

Published
2019
Full Text
View/download PDF

25. Limited Capability for Testing Mycobacterium tuberculosis for Susceptibility to New Drugs

Author

Farooq, Hamzah Z., Cirillo, Daniela M., Hillemann, Doris, Wyllie, David, van der Werf, Marieke J., Kodmon, Csaba, and Nikolayevskyy, Vlad

Subjects
Identification and classification, Research, Health aspects, Microbial drug resistance -- Identification and classification, Microbial sensitivity tests -- Research, Mycobacterium tuberculosis -- Health aspects, Drug resistance in microorganisms -- Identification and classification
Abstract

Mycobacterium tuberculosis is a major cause of death globally, and increasing predicted deaths from tuberculosis (TB) are caused by delays in diagnosis and treatment of new cases associated with coronavirus [...]

Published
2021
Full Text
View/download PDF

26. Whole genome sequencing of Mycobacterium tuberculosis: current standards and open issues

Author

Meehan, Conor J., Goig, Galo A., Kohl, Thomas A., Verboven, Lennert, Dippenaar, Anzaan, Ezewudo, Matthew, Farhat, Maha R., Guthrie, Jennifer L., Laukens, Kris, Miotto, Paolo, Ofori-Anyinam, Boatema, Dreyer, Viola, Supply, Philip, Suresh, Anita, Utpatel, Christian, van Soolingen, Dick, Zhou, Yang, Ashton, Philip M., Brites, Daniela, Cabibbe, Andrea M., de Jong, Bouke C., de Vos, Margaretha, Menardo, Fabrizio, Gagneux, Sebastien, Gao, Qian, Heupink, Tim H., Liu, Qingyun, Loiseau, Chloé, Rigouts, Leen, Rodwell, Timothy C., Tagliani, Elisa, Walker, Timothy M., Warren, Robin M., Zhao, Yanlin, Zignol, Matteo, Schito, Marco, Gardy, Jennifer, Cirillo, Daniela M., Niemann, Stefan, Comas, Inaki, and Van Rie, Annelies

Published
2019
Full Text
View/download PDF

27. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study

Author

Dorman, Susan E, Schumacher, Samuel G, Alland, David, Nabeta, Pamela, Armstrong, Derek T, King, Bonnie, Hall, Sandra L, Chakravorty, Soumitesh, Cirillo, Daniela M, Tukvadze, Nestani, Bablishvili, Nino, Stevens, Wendy, Scott, Lesley, Rodrigues, Camilla, Kazi, Mubin I, Joloba, Moses, Nakiyingi, Lydia, Nicol, Mark P, Ghebrekristos, Yonas, Anyango, Irene, Murithi, Wilfred, Dietze, Reynaldo, Peres, Renata Lyrio, Skrahina, Alena, Auchynka, Vera, Chopra, Kamal Kishore, Hanif, Mahmud, Liu, Xin, Yuan, Xing, Boehme, Catharina C, Ellner, Jerrold J, Denkinger, Claudia M, Manabe, Yukari C, Hom, David, Aspindzelashvili, Rusudan, David, Anura, Surve, Utkarsha, Kamulegeya, Louis Henry, Nabweyambo, Sheila, Surtie, Shireen, Hapeela, Nchimunya, Cain, Kevin P, Agaya, Janet, McCarthy, Kimberly D, Marques-Rodrigues, Patricia, Schmidt Castellani, Luiz Guilherme, Almeida, Pedro Sousa, Jr, de Aguiar, Paola Poloni Lobo, Solodovnikova, Varvara, Ruan, Xianglin, Liang, Lili, Zhang, Guolong, Zhu, Hong, Xie, Yingda, and Lyrio Peres, Renata

Published
2018
Full Text
View/download PDF

29. The new phylogeny of the genus Mycobacterium: The old and the news

Author

Tortoli, Enrico, Fedrizzi, Tarcisio, Meehan, Conor J., Trovato, Alberto, Grottola, Antonella, Giacobazzi, Elisabetta, Serpini, Giulia Fregni, Tagliazucchi, Sara, Fabio, Anna, Bettua, Clotilde, Bertorelli, Roberto, Frascaro, Francesca, De Sanctis, Veronica, Pecorari, Monica, Jousson, Olivier, Segata, Nicola, and Cirillo, Daniela M.

Published
2017
Full Text
View/download PDF

31. Screening of inmates transferred to Spain reveals a Peruvian prison as a reservoir of persistent Mycobacterium tuberculosis MDR strains and mixed infections

Author

Abascal, Estefanía, Herranz, Marta, Acosta, Fermín, Agapito, Juan, Cabibbe, Andrea M., Monteserin, Johana, Ruiz Serrano, María Jesús, Gijón, Paloma, Fernández-González, Francisco, Lozano, Nuria, Chiner-Oms, Álvaro, Cáceres, Tatiana, Pintado, Pilar Gómez, Acín, Enrique, Valencia, Eddy, Muñoz, Patricia, Comas, Iñaki, Cirillo, Daniela M., Ritacco, Viviana, Gotuzzo, Eduardo, and García de Viedma, Darío

Published
2020
Full Text
View/download PDF

37. Tuberculosis Treatment Monitoring and Outcome Measures: New Interest and New Strategies

Author

Heyckendorf, Jan, Georghiou, Sophia B., Frahm, Nicole, Heinrich, Norbert, Kontsevaya, Irina, Reimann, Maja, Holtzman, David, Imperial, Marjorie, Cirillo, Daniela M., Gillespie, Stephen H., and Ruhwald, Morten

Subjects
Microbiology (medical), Treatment Outcome, Infectious Diseases, General Immunology and Microbiology, Epidemiology, Antitubercular Agents, Public Health, Environmental and Occupational Health, Humans, Tuberculosis, Review, Mycobacterium tuberculosis, Hazardous Substances
Abstract

Despite the advent of new diagnostics, drugs and regimens, tuberculosis (TB) remains a global public health threat. A significant challenge for TB control efforts has been the monitoring of TB therapy and determination of TB treatment success. Current recommendations for TB treatment monitoring rely on sputum and culture conversion, which have low sensitivity and long turnaround times, present biohazard risk, and are prone to contamination, undermining their usefulness as clinical treatment monitoring tools and for drug development. We review the pipeline of molecular technologies and assays that serve as suitable substitutes for current culture-based readouts for treatment response and outcome with the potential to change TB therapy monitoring and accelerate drug development.

Published
2022
Full Text
View/download PDF

40. Optimising tuberculosis care for refugees affected by armed conflicts

Author

Castro, Kenneth G, Ditiu, Lucica, Sahu, Suvanand, Ntoumi, Francine, Tiberi, Simon, O'Kane, Cecilia M, Akkerman, Onno, Manika, Katerina, Mwaba, Peter, Davies Forsman, Lina, Petersen, Eskild, Aklillu, Eleni, Azhar, Esam I, Cirillo, Daniela M, Migliori, Giovanni-Battista, Abbara, Aula, and Zumla, Alimuddin

Published
2022
Full Text
View/download PDF

42. Dynamic antibody responses to the Mycobacterium tuberculosis proteome

Author

Kunnath-Velayudhan, Shajo, Salamon, Hugh, Wang, Hui-Yun, Davidow, Amy L., Molina, Douglas M., Huynh, Vu T., Cirillo, Daniela M., Michel, Gerd, Talbot, Elizabeth A., Perkins, Mark D., Felgner, Philip L., Liang, Xiaowu, Gennaro, Maria L., and Rappuoli, Rino

Published
2010

45. Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment

Author

Ministerio de Ciencia e Innovación (España), European Research Council, Comas, Iñaki [0000-0001-5504-9408], Antimycobacterial Susceptibility Testing Group, Georghiou, Sophia B., Rodwell, Timothy C., Korobitsyn, Alexei, Abbadi, Said H., Ajbani, Kanchan, Alffenaar, Jan-Willem, Alland, David, Alvarez, Nataly, Andres, Sönke, Ardizzoni, Elisa, Aubry, Alexandra, Baldan, Rossella, Ballif, Marie, Barilar, Ivan, Böttger, Erik C., Chakravorty, Soumitesh, Claxton, Pauline M., Cirillo, Daniela M., Comas, Iñaki, Coulter, Chris, Denkinger, Claudia M., Derendinger, Brigitta, Desmond, Edward P., Steenwinkel, Jurriaan E. M. de, Dheda, Keertan, Diacon, Andreas H., Dolinger, David L., Dooley, Kelly E., Egger, Matthias, Ehsani, Soudeh, Farhat, Maha R., Fattorini, Lanfranco, Finci, Iris, Fournier Le Ray, Laure, Furió, Victoria, Groenheit, Ramona, Gumbo, Tawanda, Heysell, Scott K., Hillemann, Doris, Hoffmann, Harald, Hsueh, Po-Ren, Hu, Yi, Huang, Hairong, Hussain, Alamdar, Ismail, Farzana, Izumi, Kiyohiko, Jagielski, Tomasz, Johnson, John L., Kambli, Priti, Kaniga, Koné, Karunaratne, G. H. R. Eranga, Sharma, Meenu Kaushal, Keller, Peter M., Kelly, Ellis C., Kholina, Margarita, Kohli, Mikashmi, Kranzer, Katharina, Laurenson, Ian F., Limberis, Jason, Lin, S-Y. Grace, Liu, Yongge, López-Gavín, Alexandre, Lyander, Anna, Machado, Diana, Martínez, Elena, Masood, Faisal, Mitarai, Satoshi, Mvelase, Nomonde R., Niemann, Stefan, Nikolayevskyy, Vladyslav, Maurer, Florian P., Merker, Matthias, Miotto, Paolo, Omar, Shaheed V., Otto-Knapp, Ralf, Palaci, Moisés, Palacios Gutiérrez, Juan José, Peacock, Sharon J., Peloquin, Charles A., Perera, Jennifer, Pierre-Audigier, Catherine, Pholwat, Suporn, Posey, James E., Prammananan, Therdsak, Rigouts, Leen, Robledo, Jaime, Rockwood, Neesha, Rodrigues, Camilla, Salfinger, Max, Schechter, Marcos C., Seifert, Marva, Sengstake, Sarah, Shinnick, Thomas, Shubladze, Natalia, Sintchenko, Vitali, Sirgel, Frederick, Somasundaram, Sulochana, Sterling, Timothy R., Spitaleri, Andrea, Streicher, Elizabeth, Supply, Philip, Svensson, Erik, Tagliani, Elisa, Tahseen, Sabira, Takaki, Akiko, Theron, Grant, Torrea, Gabriela, Van Deun, Armand, van Ingen, Jakko, Van Rie, Annelies, van Soolingen, Dick, Vargas Jr, Roger, Venter, Amour, Veziris, Nicolas, Villellas, Cristina, Viveiros, Miguel, Warren, Robin, Wen, Shu'an, Werngren, Jim, Wilkinson, Robert J., Yang, Caie, Yılmaz, F. Ferda, Zhang, Tingting, Zimenkov, Danila, Ismail, Nazir, Köser, Claudio U., Schön, Thomas, Ministerio de Ciencia e Innovación (España), European Research Council, Comas, Iñaki [0000-0001-5504-9408], Antimycobacterial Susceptibility Testing Group, Georghiou, Sophia B., Rodwell, Timothy C., Korobitsyn, Alexei, Abbadi, Said H., Ajbani, Kanchan, Alffenaar, Jan-Willem, Alland, David, Alvarez, Nataly, Andres, Sönke, Ardizzoni, Elisa, Aubry, Alexandra, Baldan, Rossella, Ballif, Marie, Barilar, Ivan, Böttger, Erik C., Chakravorty, Soumitesh, Claxton, Pauline M., Cirillo, Daniela M., Comas, Iñaki, Coulter, Chris, Denkinger, Claudia M., Derendinger, Brigitta, Desmond, Edward P., Steenwinkel, Jurriaan E. M. de, Dheda, Keertan, Diacon, Andreas H., Dolinger, David L., Dooley, Kelly E., Egger, Matthias, Ehsani, Soudeh, Farhat, Maha R., Fattorini, Lanfranco, Finci, Iris, Fournier Le Ray, Laure, Furió, Victoria, Groenheit, Ramona, Gumbo, Tawanda, Heysell, Scott K., Hillemann, Doris, Hoffmann, Harald, Hsueh, Po-Ren, Hu, Yi, Huang, Hairong, Hussain, Alamdar, Ismail, Farzana, Izumi, Kiyohiko, Jagielski, Tomasz, Johnson, John L., Kambli, Priti, Kaniga, Koné, Karunaratne, G. H. R. Eranga, Sharma, Meenu Kaushal, Keller, Peter M., Kelly, Ellis C., Kholina, Margarita, Kohli, Mikashmi, Kranzer, Katharina, Laurenson, Ian F., Limberis, Jason, Lin, S-Y. Grace, Liu, Yongge, López-Gavín, Alexandre, Lyander, Anna, Machado, Diana, Martínez, Elena, Masood, Faisal, Mitarai, Satoshi, Mvelase, Nomonde R., Niemann, Stefan, Nikolayevskyy, Vladyslav, Maurer, Florian P., Merker, Matthias, Miotto, Paolo, Omar, Shaheed V., Otto-Knapp, Ralf, Palaci, Moisés, Palacios Gutiérrez, Juan José, Peacock, Sharon J., Peloquin, Charles A., Perera, Jennifer, Pierre-Audigier, Catherine, Pholwat, Suporn, Posey, James E., Prammananan, Therdsak, Rigouts, Leen, Robledo, Jaime, Rockwood, Neesha, Rodrigues, Camilla, Salfinger, Max, Schechter, Marcos C., Seifert, Marva, Sengstake, Sarah, Shinnick, Thomas, Shubladze, Natalia, Sintchenko, Vitali, Sirgel, Frederick, Somasundaram, Sulochana, Sterling, Timothy R., Spitaleri, Andrea, Streicher, Elizabeth, Supply, Philip, Svensson, Erik, Tagliani, Elisa, Tahseen, Sabira, Takaki, Akiko, Theron, Grant, Torrea, Gabriela, Van Deun, Armand, van Ingen, Jakko, Van Rie, Annelies, van Soolingen, Dick, Vargas Jr, Roger, Venter, Amour, Veziris, Nicolas, Villellas, Cristina, Viveiros, Miguel, Warren, Robin, Wen, Shu'an, Werngren, Jim, Wilkinson, Robert J., Yang, Caie, Yılmaz, F. Ferda, Zhang, Tingting, Zimenkov, Danila, Ismail, Nazir, Köser, Claudio U., and Schön, Thomas

Abstract

Inappropriately high breakpoints have resulted in systematic false-susceptible AST results to anti-TB drugs. MIC, PK/PD and clinical outcome data should be combined when setting breakpoints to minimise the emergence and spread of antimicrobial resistance.

Published
2022

47. Longitudinal analysis of T cell receptor repertoires reveals shared patterns of antigen-specific response to SARS-CoV-2 infection

Author

Gittelman, Rachel M., primary, Lavezzo, Enrico, additional, Snyder, Thomas M., additional, Zahid, H. Jabran, additional, Carty, Cara L., additional, Elyanow, Rebecca, additional, Dalai, Sudeb, additional, Kirsch, Ilan, additional, Baldo, Lance, additional, Manuto, Laura, additional, Franchin, Elisa, additional, Del Vecchio, Claudia, additional, Pacenti, Monia, additional, Boldrin, Caterina, additional, Cattai, Margherita, additional, Saluzzo, Francesca, additional, Padoan, Andrea, additional, Plebani, Mario, additional, Simeoni, Fabio, additional, Bordini, Jessica, additional, Lorè, Nicola I., additional, Lazarević, Dejan, additional, Cirillo, Daniela M., additional, Ghia, Paolo, additional, Toppo, Stefano, additional, Carlson, Jonathan M., additional, Robins, Harlan S., additional, Crisanti, Andrea, additional, and Tonon, Giovanni, additional

Published
2022
Full Text
View/download PDF

48. Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment

Author

Antimycobacterial Susceptibility Testing Group, Georghiou, Sophia B., Rodwell, Timothy C., Korobitsyn, Alexei, Abbadi, Said H., Ajbani, Kanchan, Alffenaar, Jan-Willem, Alland, David, Alvarez, Nataly, Andres, Sönke, Ardizzoni, Elisa, Aubry, Alexandra, Baldan, Rossella, Ballif, Marie, Barilar, Ivan, Böttger, Erik C., Chakravorty, Soumitesh, Claxton, Pauline M., Cirillo, Daniela M., Comas, Iñaki, Coulter, Chris, Denkinger, Claudia M., Derendinger, Brigitta, Desmond, Edward P., Steenwinkel, Jurriaan E. M. de, Dheda, Keertan, Diacon, Andreas H., Dolinger, David L., Dooley, Kelly E., Egger, Matthias, Ehsani, Soudeh, Farhat, Maha R., Fattorini, Lanfranco, Finci, Iris, Fournier Le Ray, Laure, Furió, Victoria, Groenheit, Ramona, Gumbo, Tawanda, Heysell, Scott K., Hillemann, Doris, Hoffmann, Harald, Hsueh, Po-Ren, Hu, Yi, Huang, Hairong, Hussain, Alamdar, Ismail, Farzana, Izumi, Kiyohiko, Jagielski, Tomasz, Johnson, John L., Kambli, Priti, Kaniga, Koné, Karunaratne, G. H. R. Eranga, Sharma, Meenu Kaushal, Keller, Peter M., Kelly, Ellis C., Kholina, Margarita, Kohli, Mikashmi, Kranzer, Katharina, Laurenson, Ian F., Limberis, Jason, Lin, S-Y. Grace, Liu, Yongge, López-Gavín, Alexandre, Lyander, Anna, Machado, Diana, Martínez, Elena, Masood, Faisal, Mitarai, Satoshi, Mvelase, Nomonde R., Niemann, Stefan, Nikolayevskyy, Vladyslav, Maurer, Florian P., Merker, Matthias, Miotto, Paolo, Omar, Shaheed V., Otto-Knapp, Ralf, Palaci, Moisés, Palacios Gutiérrez, Juan José, Peacock, Sharon J., Peloquin, Charles A., Perera, Jennifer, Pierre-Audigier, Catherine, Pholwat, Suporn, Posey, James E., Prammananan, Therdsak, Rigouts, Leen, Robledo, Jaime, Rockwood, Neesha, Rodrigues, Camilla, Salfinger, Max, Schechter, Marcos C., Seifert, Marva, Sengstake, Sarah, Shinnick, Thomas, Shubladze, Natalia, Sintchenko, Vitali, Sirgel, Frederick, Somasundaram, Sulochana, Sterling, Timothy R., Spitaleri, Andrea, Streicher, Elizabeth, Supply, Philip, Svensson, Erik, Tagliani, Elisa, Tahseen, Sabira, Takaki, Akiko, Theron, Grant, Torrea, Gabriela, Van Deun, Armand, van Ingen, Jakko, Van Rie, Annelies, van Soolingen, Dick, Vargas Jr, Roger, Venter, Amour, Veziris, Nicolas, Villellas, Cristina, Viveiros, Miguel, Warren, Robin, Wen, Shu'an, Werngren, Jim, Wilkinson, Robert J., Yang, Caie, Yılmaz, F. Ferda, Zhang, Tingting, Zimenkov, Danila, Ismail, Nazir, Köser, Claudio U., Schön, Thomas, University of Zurich, Antimycobacterial Susceptibility Testing Group, Department of Genetics [Cambridge], University of Cambridge [UK] (CAM), Centre d'Immunologie et des Maladies Infectieuses (CIMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Médical de l'Institut Pasteur (CMIP), Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité), Institut de médecine et d'épidémiologie appliquée [AP-HP Hôpital Bichat-Claude Bernard] (IMEA), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 (CIIL), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Centre National de la Recherche Scientifique (CNRS), As current or former employees or consultants for FIND, the work of R.B. Baldan, I. Comas, C.M. Denkinger, D.L. Dolinger, S.B. Georghiou, C.U. Köser and T.C. Rodwell on the systematic reviews, including this viewpoint, was supported by Unitaid (grant 2019-32-FIND MDR), BMGF (grant OPP1105925), the German Federal Ministry of Education and Research through KfW, the Dutch Ministry of Foreign Affairs, the Australian Department of Foreign Affairs and Trade, and UK aid from the British people. N. Alvarez and J. Robledo are funded by MinCiencias, Colombia (number 221389666216 CT-783-2018). A. Aubry and N. Veziris work at the Centre National de Reference des Mycobactéries, which receives an annual grant from Santé Publique France and have received research grants from Janssen for studies on bedaquiline. P. Claxton and I.F. Laurenson are funded through National Services Scotland. I. Comas was supported by PID2019-104477RB-I00 from the Spanish Science Ministry and by ERC (CoG 101001038). M. Egger is supported by the Swiss National Science Foundation (grant number 320030_153442 and 189498) and the US National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Cancer Institute, the National Institute of Mental Health, the National Institute on Drug Abuse, the National Heart, Lung, and Blood Institute, the National Institute on Alcohol Abuse and Alcoholism, the National Institute of Diabetes and Digestive and Kidney Diseases, the Fogarty International Center, and the National Library of Medicine: Asia-Pacific, U01AI069907, CCASAnet, U01AI069923, Central Africa, U01AI096299, East Africa, U01AI069911, NA-ACCORD, U01AI069918, Southern Africa, U01AI069924, West Africa, U01AI069919. M.R. Farhat is supported by NIH NIAID R01AI155765. S.K. Heysell was funded by NIH NIAID grants R01 AI137080 and U01 AI150508. T. Jagielski was supported by a DAINA grant (number 2017/27/L/NZ6/03279) from the National Science Centre, Poland. J.L. Johnson was supported by contracts NO1-AI95383 and NO1-AI-70022 of the US National Institutes of Health. P.M. Keller was supported by Innosuisse 36198.1 IP-LS. C.U. Köser is a research associate at Wolfson College and visiting scientist at the Department of Genetics, University of Cambridge. The Federal Government of Germany supported C.U. Köser as part of his work for the European Laboratory Initiative, WHO Regional Office for Europe. C.U. Köser was further supported by the Royal Society of Tropical Medicine and Hygiene and the National Institute for Health Research Cambridge Biomedical Research Centre and received an observership by the European Society of Clinical Microbiology and Infectious Diseases to the EUCAST Development Laboratory for Bacteria (Växjö, Sweden), hosted by Gunnar Kahlmeter and Erika Matuschek. D. Machado and M. Viveiros are funded in part by Fundação para a Ciência e a Tecnologia, Portugal (PTDC/BIA-MIC/30692/2017, UID/Multi/04413/2020 and DL57/ CEECIND/0256/2017). S. Niemann is supported by the German Center for Infection Research, Excellenz Cluster Precision Medicine in Chronic Inflammation EXC 2167, Leibniz Science Campus Evolutionary Medicine of the LUNG (EvoLUNG). S.V. Omar has received funding to prepare and provide training for Janssen Pharmaceutica activities. L. Rigouts is supported by the Belgian Directorate General for Development. T.C. Rodwell was additionally funded in part by FIND and NIH NIAD, grants: P30 AI036214 and R21 AI135756. T. Schön is funded by the Swedish Heart and Lung Foundation and the Swedish Research Council. T.R. Sterling has received funding from the US National Institutes of Health and the Centers for Disease Control and Prevention. G. Theron and R. Warren are supported by baseline funding from the South African Medical Research Council. R.J. Wilkinson receives funding from the Wellcome Trust (203135) and from the Francis Crick Institute, which is supported by Cancer Research UK (FC0010218), UKRI (FC0010218) and the Wellcome Trust (FC0010218), Ministerio de Ciencia e Innovación (España), European Research Council, Comas, Iñaki, Comas, Iñaki [0000-0001-5504-9408], Antimycobacterial Susceptibility T, and Wellcome Trust

Subjects
[SDV]Life Sciences [q-bio], Respiratory System, Drug Resistance, Antitubercular Agents, Infektionsmedicin, Medical and Health Sciences, Drug Resistance, Multiple, Bacterial, Tuberculosis, Multidrug-Resistant, 11 Medical and Health Sciences, Human Biology & Physiology, MESH: Microbial Sensitivity Tests, 10179 Institute of Medical Microbiology, Bacterial, Multidrug-Resistant, Infectious Diseases, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Infection, Life Sciences & Biomedicine, Multiple, Model organisms, Pulmonary and Respiratory Medicine, Infectious Medicine, Immunology, Infectious Disease, 610 Medicine & health, Microbial Sensitivity Tests, Vaccine Related, Rare Diseases, Clinical Research, Biodefense, MESH: Drug Resistance, Bacterial, Drug Resistance, Bacterial, Tuberculosis, Humans, Science & Technology, MESH: Humans, Antimycobacterial Susceptibility Testing Group, FOS: Clinical medicine, Prevention, MESH: Drug Resistance, Multiple, Bacterial, Mycobacterium tuberculosis, Eucast, MESH: Antitubercular Agents, lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], Orphan Drug, Emerging Infectious Diseases, Good Health and Well Being, 2740 Pulmonary and Respiratory Medicine, 570 Life sciences, biology, Human medicine, Antimicrobial Resistance, Model
Abstract

11 páginas, 2 figuras, 1 tabla, Inappropriately high breakpoints have resulted in systematic false-susceptible AST results to anti-TB drugs. MIC, PK/PD and clinical outcome data should be combined when setting breakpoints to minimise the emergence and spread of antimicrobial resistance., I. Comas was supported by PID2019-104477RB-I00 from the Spanish Science Ministry and by ERC (CoG 101001038)

Published
2022
Full Text
View/download PDF

49. Combined Host- and Pathogen-Directed Therapy for the Control of Mycobacterium abscessus Infection

Author

Poerio, Noemi, primary, Riva, Camilla, additional, Olimpieri, Tommaso, additional, Rossi, Marco, additional, Lorè, Nicola I., additional, De Santis, Federica, additional, Henrici De Angelis, Lucia, additional, Ciciriello, Fabiana, additional, D’Andrea, Marco M., additional, Lucidi, Vincenzina, additional, Cirillo, Daniela M., additional, and Fraziano, Maurizio, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results